Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 19:57:101180.
doi: 10.1016/j.lanwpc.2024.101180. eCollection 2025 Apr.

Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review

Rui-Chen Xu  1   2 , Yan-Wu Zhang  3 , Cui-Cui Liu  1   2 , Ying-Ying Xu  4 , Zhi-Ming Shao  1   2 , Ke-Da Yu  1   2
Affiliations
Review

Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review

Rui-Chen Xu et al. Lancet Reg Health West Pac. .

Abstract

Immunotherapy, including immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, and other modalities, represents a significant advancement in cancer treatment. Breast cancer, traditionally considered less amenable to immunotherapy, has demonstrated responsiveness to immunotherapy when combined with conventional treatment options. These integrative strategies enhance the effectiveness of immunotherapy, bringing hope to patients. Furthermore, precision therapies guided by predictive biomarkers refine the scope of breast cancer immunotherapy and broaden its advantages. Notably, it is essential to recognise the differences in breast cancer epidemiology, clinical outcomes, and molecular signatures between Asian populations and those in Europe and North America. These include a higher proportion of premenopausal patients and variation in subtype distribution and gene mutation profiles, underscoring the importance of considering racial specificity in immunotherapy. Clinical efforts in Asia, supported by ethnicity-specific studies, indigenous immunotherapeutic agents, and precision medicine informed by predictive biomarkers, provide tailored treatment options. This review aims to present an overview of breast cancer immunotherapy while address the racial specificity to inform its application for Asian patients.

Keywords: Breast cancer; Immune checkpoint inhibitors; Immunotherapy; Racial specificity; Triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow chart of references and ongoing trials selection.
See this image and copyright information in PMC

References

    1. Harbeck N., Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. - PubMed
    1. Amaria R.N., Postow M., Burton E.M., et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611(7934):155–160. - PMC - PubMed
    1. Goldhirsch A., Winer E.P., Coates A.S., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–2223. - PMC - PubMed
    1. Liu Y., Hu Y., Xue J., et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22(1):145. - PMC - PubMed
    1. Adams S., Schmid P., Rugo H.S., et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404. - PubMed

LinkOut - more resources